A lthough screening for elevated LDL cholesterol (LDL-C) remains a major component of national guidelines for the prevention of coronary heart disease (CHD), LDL-C level is insufficient to identify individuals who would develop CHD, because many CHD events occur in individuals without elevated LDL-C, 1 indicating the influence of other risk factors. Inflammation plays an important role in both atherogenesis and atherothrombotic events, and several biomarkers of inflammation, including high-sensitivity C-reactive protein (hs-CRP), 2 interleukin-6, 3 and soluble intercellular adhesion molecule-1, 4 have been associated with increased risk for CHD events. hs-CRP measurement has been recommended for some patients to refine risk assessment 5 because hs-CRP levels have been shown to provide additional predictive information beyond traditional risk factors such as LDL-C. 6 Increased hs-CRP levels may also be useful to identify patients with low LDL-C who are at increased CHD risk and may benefit from statin therapy. 7 Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme that can hydrolyze oxidized phospholipids to generate lysophosphatidylcholine and oxidized fatty acids, which have proinflammatory properties. However, hydrolysis of platelet-activating factor and other phospholipids by Lp-PLA 2 could also reduce inflammation, 8 and it is not clear whether Lp-PLA 2 is proinflammatory or anti-inflammatory in humans.
Lp-PLA 2 is associated primarily with LDL, and enzyme activity is increased in small, dense LDL. 9 In a case-cohort analysis of the West of Scotland Coronary Prevention Study (WOSCOPS), high baseline Lp-PLA 2 levels were associated with increased risk for CHD events, even after adjustment for traditional risk factors and hs-CRP. 10 In a case-control analysis from the Women's Health Study, baseline Lp-PLA 2 levels were higher in women with subsequent cardiovascular events but were not associated with increased CHD risk after adjustment for traditional risk factors and hs-CRP. 11 The purpose of this study was to examine whether levels of Lp-PLA 2 and hs-CRP in middle-aged American men and women were associated with increased risk for incident CHD in the Atherosclerosis Risk in Communities (ARIC) study.
Methods

Study Population
The ARIC design, objectives, sampling strategies, and examination techniques have been described previously. 12 ARIC is a large, biracial cohort study of 15 792 adults 45 to 64 years old. A baseline examination was conducted in 1987 to 1989, with 3 more examinations through 1998.
Participants were followed up for incident CHD, defined by combinations of chest pain, ECG changes, cardiac enzyme levels, and surgical revascularization. Potential CHD events were reviewed by 2 members of the ARIC Morbidity and Mortality Classification Committee, and any differences between reviewers were adjudicated by the committee chairperson.
Study Design
Because plasma samples from the first visit were depleted, Lp-PLA 2 and hs-CRP were measured in duplicate in plasma from visit 2 (1990 -1992) in individuals who subsequently developed a CHD event (cases) and in a cohort random sample (CRS). Of the 14 560 participants with visit 2 data, 1272 were excluded because of CHD or missing CHD information before visit 2, 376 for transient ischemic attack or stroke, and 93 who belonged to an underrepresented minority group. The potential full cohort consisted of 12 819 individuals who were followed up for the subsequent development of a CHD event, including CHD-related death. Subjects alive and event-free at the end of 1998 or lost to follow-up were censored. We constructed a case-cohort design (nϭ1652) 13 in which cases are compared with a CRS of all participants at the beginning of follow-up. The case-cohort design has the advantages that a single comparison group can be used for multiple disease outcomes (such as incident CHD and stroke), the comparison group is representative of the entire study population, and both absolute risks and relative hazards can be obtained with appropriate statistical analyses.
We selected the CRS by stratification on sex, race (black versus white) and age at baseline (Ն55 versus Ͻ55). After exclusion of 304 subjects with missing information, the final sample size for the analysis was 1348 (608 cases and 740 noncases). The CRS included 785 individuals: 45 cases and all 740 noncases.
Risk Factor Assessment
Information about medical history, cigarette smoking, and alcohol consumption was based on standardized, validated intervieweradministered questionnaires at visit 2. Body mass index (BMI) was derived from measured height and weight. Hypertension was defined as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or use of antihypertensive medication in the previous 2 weeks. Diabetes was defined as fasting blood glucose Ն126 mg/dL, nonfasting blood glucose Ն200 mg/dL, a physician's diagnosis of diabetes, or use of antidiabetic medication in the previous 2 weeks.
Laboratory Measurements
Plasma lipids were measured in centralized laboratories by standard, validated methods reported previously. 14 -16 Lp-PLA 2 was assessed by a dual monoclonal antibody immunoassay standardized to recombinant Lp-PLA 2 (PLAC test, diaDexus, Inc). 17 To assess interassay precision for Lp-PLA 2 measurement, 2 controls of known concentration (low and high) were measured in 40 separate assays. The interassay coefficient of variation on all 40 plates was 12.7% and 9.6%, respectively. hs-CRP was assessed by the immunoturbidimetric CRP-Latex (II) hs assay from Denka Seiken using a Hitachi 911 analyzer. The assay was performed according to the manufacturer's protocol and has been validated against the Dade-Behring method. 18 For quality control, in addition to the measurement of each sample in duplicate, Ϸ6% of samples were measured as blinded replicates on different dates to assess repeatability of measurements of Lp-PLA 2 , hs-CRP, and other analytes. The reliability coefficient for blinded quality control replicates was 0.76 for the Lp-PLA 2 assay (67 blinded replicates) and 0.95 for the hs-CRP assay (70 blinded replicates).
Statistical Analyses
For the primary analysis, all variables were categorized, with cutpoints taken from the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines for cholesterol 19 and the Joint National Committee VI guidelines for blood pressure. 20 Some categories were combined to maintain sufficient numbers of events per cell. Tertiles of the major study covariate, Lp-PLA 2 , were used. For hs-CRP, both tertiles and American Heart Association (AHA)/Centers for Disease Control and Prevention (CDC) cutpoints 5 were examined. Covariates also were treated as continuous to examine the potential (non)linear trend in ancillary analyses. The primary null hypothesis was that Lp-PLA 2 is not predictive of CHD events, over and above a set of traditional risk factors included in the model, with special attention to the interrelationship of Lp-PLA 2 with LDL-C and hs-CRP. The association was tested at the 0.05 level using a Wald test for the 2-sided alternative.
Crude and adjusted (for demographic factors: race, sex, age) means or proportions of baseline variables were examined in cases versus noncases using ANCOVA and logistic regression. 21 Beyond basic demographic variables, variables for risk factors recommended by ATP III 19 for CHD risk assessment were considered as potential confounders: LDL-C, HDL cholesterol (HDL-C), total cholesterol, diabetes, smoking, and hypertension. Weighted Pearson and Spearman's rank correlation coefficients were computed between variables among subjects in the CRS. In all analyses, weighting schemes based on sampling proportions were used so that the resulting inferences were pertinent to the entire cohort.
For the association between Lp-PLA 2 level and incident CHD, the Cox proportional hazards model was used to investigate the independent and joint prognostic effects, accounting for the fact that all incident CHD cases are included but only a stratified random sample of the full cohort. The statistical method and computer software used were developed for case-cohort design within a framework of proportional hazard regression, with an appropriate modification to take into account the stratified nature of the CRS and robust variance estimation. 22, 23 The results were summarized as hazard ratios (HRs) with 95% CIs.
Tests for various potential interactions and (non)linearity were conducted as a secondary analysis, and subgroup analyses were considered to confirm findings. For the overall association of Lp-PLA 2 and outcome, a 2 test statistic was calculated. All other overall associations were tested similarly. SAS version 8 was used for all statistical analyses, except that SUDAAN version 8.0.0 was used to compute probability values for weighted correlation coefficients.
teristics of the study population are shown in Table 1 . Compared with noncases, individuals with incident CHD had significantly higher BMI, systolic blood pressure, and levels of total cholesterol, triglycerides, and LDL-C and significantly lower HDL-C levels. Hypertension, diabetes, and current smoking were more prevalent in CHD cases. In addition to these differences in traditional risk factors, the weighted mean levels of both Lp-PLA 2 and hs-CRP were higher in cases than noncases, 404 versus 372 g/L and 4.05 versus 3.04 mg/L, respectively.
Lp-PLA 2 level was positively correlated with LDL-C (rϭ0.36) and total cholesterol (rϭ0.23) levels and negatively correlated with HDL-C level (rϭϪ0.33) in both men and women (Table 2 ). There was a weak positive correlation with triglyceride (rϭ0.13) and no significant correlation with hs-CRP or BMI. Spearman's rank correlation gave similar results. Weighted mean Lp-PLA 2 was 421 g/L in men and 339 g/L in women, 366 g/L in individuals Ͻ55 years old and 384 g/L in individuals Ն55 years old, 388 g/L in whites and 333 g/L in African Americans, 362 g/L in diabetics and 376 g/L in nondiabetics, and 404 g/L in current smokers and 366 g/L in nonsmokers.
Because hs-CRP tertiles in ARIC (Ͻ1.01, 1.01 to 2.82, and Ͼ2.82 mg/L) were similar to the cutpoints defined in the AHA/CDC guidelines (Ͻ1 mg/L, 1 to 3 mg/L, Ͼ3 mg/L), 5 the AHA/CDC cutpoints were used to facilitate comparison across studies. In a Cox proportional hazards model adjusted for age, sex, and race, high hs-CRP as defined by the AHA/CDC cutpoint of Ͼ3.0 mg/L was associated with a significant increase in risk (2.53 HR, 95% CI 1.88 to 3.40) ( Table 3) . Further adjustment for smoking, hypertension, diabetes, LDL-C, and HDL-C attenuated risk associated with high hs-CRP, but risk remained significantly elevated (1.72 HR, 95% CI 1.24 to 2.39). For individuals with LDL-C Ͻ130 mg/dL, approximately the median LDL-C in this population, high hs-CRP was associated with increased CHD risk (1.76 HR, 95% CI 1.02 to 3.03). The use of tertiles for hs-CRP and the addition of BMI to the model did not significantly alter the findings (data not shown).
Lp-PLA 2 levels in the highest tertile (Ն422 g/L) were associated with increased CHD risk (1.78 HR, 95% CI 1.33 to 2.38) in a model adjusted for age, sex, and race (Table 4) . In a Cox proportional hazards model also adjusted for traditional risk factors, including LDL-C and HDL-C, the relative risk associated with the upper tertile of Lp-PLA 2 was attenuated and no longer significant. Tests for potential interaction with variables used in the model showed no interaction with race or sex but a significant 3-way interaction of Lp-PLA 2 with hs-CRP and LDL-C (Pϭ0.02); therefore, subgroup analysis defined by LDL-C categories (Ͻ130 and Ն130 mg/dL) was performed. No significant Lp-PLA 2 associations were seen for individuals with higher LDL-C. However, for individuals with low LDL-C (Ͻ130 mg/dL), elevated Lp-PLA 2 was associated with a significantly higher risk for incident CHD (1.99 HR, 95% CI 1.17 to 3.38), and even after further adjustment of the model to include hs-CRP, elevated Lp-PLA 2 remained associated with increased CHD risk (2.08 HR, 95% CI 1.20 to 3.62) in these individuals. Inclusion of BMI in the model did not alter these findings. To address the impact of the 3-way effect modification, we added the interaction of Lp-PLA 2 and hs-CRP in the model, which was restricted to the subgroup with low LDL-C. Results of this model with dichotomized conditions are illustrated in Figure  1 ; individuals with low LDL-C who were in the highest tertile of both Lp-PLA 2 and hs-CRP were at the highest risk for CHD events (2.95 HR, 95% CI 1.47 to 5.94) compared with those in the lower 2 tertiles for both. Individuals with either high Lp-PLA 2 (Ն422 g/L) and low to average hs-CRP (Յ3 mg/L) or high hs-CRP (Ͼ3 mg/L) and low to medium Lp-PLA 2 (Ͻ422 g/L) did not have markedly increased risk compared with those with low to medium levels of both (Figure) . The addition of BMI and triglycerides did not significantly influence the regression analyses for hs-CRP or Lp-PLA 2 .
Discussion
In the ARIC study, Lp-PLA 2 and hs-CRP levels were higher in middle-aged American men and women who subsequently developed CHD events than in those who remained free of CHD.
Two previous studies have examined Lp-PLA 2 and hs-CRP levels in cases with incident CHD and controls, and both studies found positive associations of Lp-PLA 2 and hs-CRP with CHD risk. 10, 11 In ARIC, both Lp-PLA 2 and hs-CRP were associated with incident CHD after adjustment for age, sex, and race, with 1.78 HR (95% CI 1.33 to 2.38) for the highest Lp-PLA 2 tertile (Ն422 g/L) and 2.53 HR (95% CI 1.88 to 3.40) for hs-CRP Ͼ3.0 mg/L. The HRs for high Lp-PLA 2 in this study are similar to those reported in WOSCOPS 10 and the Women's Health Study 11 in the unadjusted models. Although all 3 studies found that Lp-PLA 2 levels were increased in individuals with subsequent CHD events, results varied among the studies when statistical models examined whether Lp-PLA 2 level had additional predictivity beyond traditional risk factors. In WOSCOPS, Lp-PLA 2 remained a significant predictor after adjustment for traditional risk factors and inflammatory factors, including hs-CRP. 10 However, in the Women's Health Study, the predictivity of Lp-PLA 2 was no longer statistically significant after adjustment for cardiovascular risk factors. 11 In the ARIC study, the relation between Lp-PLA 2 and CHD risk was attenuated after adjustment for traditional risk factors including LDL-C and HDL-C, but further analysis motivated by the significant interactions among Lp-PLA 2 , hs-CRP, and LDL-C indicated that the association remained significant, independent of other traditional risk factors but modifiable by hs-CRP in individuals with low LDL-C (Ͻ130 mg/dL). We did not find any significant, meaningful nonlinearity of Lp-PLA 2 using polynomial and spline regression, but complex nonlinearity remains a possibility. Moreover, the significant 3-way interaction (Pϭ0.02 in a model with categorical variables and Pϭ0.001 in a model with continuous variables) needs more statistical investigation in future research in this and other populations. The differing results among these studies may be attributed to the markedly different populations. WOSCOPS enrolled middle-aged hypercholesterolemic men in Scotland, with LDL-C entry criterion within a narrow range of 174 to 232 mg/dL, high prevalence of other risk factors, and 5-year event rate of 7.9% in the placebo group (1.6%/yr). 24 In addition, half the patients in WOSCOPS were assigned to pravastatin therapy, which lowered LDL-C by 26% on average. The Women's Health Study examined middle-aged American women who were mostly professionals and had a lower event rate (1.4% over 6.2 years, or 0.2%/yr), 11 enrolled fewer African Americans (2.3%) and fewer diabetic patients (2.6%) 25 than ARIC, and included only 123 cases (49 of which were stroke) and 123 controls in the Lp-PLA 2 analysis. 11 In contrast, participants in ARIC were both men and women, including a substantial number of African Americans, and had a wide range of LDL-C levels, as would be expected in the US population; in this analysis of ARIC, the 10th percentile for LDL-C was 89 mg/dL and the 90th percentile was 179 mg/dL, and the event rate was 6.1% over 7 years, or 0.9%/yr.
For the hs-CRP analysis, the cutpoints defined in the AHA/CDC guidelines (1 and 3 mg/L) 5 were used because they were similar to the tertile cutpoints in ARIC (1.01 and 2.82 mg/L). A previous analysis that examined hs-CRP in a different ARIC cohort showed similar risk for the upper 2 quintiles. 26 The AHA/CDC guidelines provide for the assessment of hs-CRP in individuals at intermediate CHD risk (10% to 20% 10-year risk) as an adjunct to major risk factors to refine risk assessment and in considering whether to Association of Lp-PLA 2 and hs-CRP with incident CHD in patients with low LDL-C (Ͻ130 mg/dL). CHD risk in individuals with elevations in both Lp-PLA 2 (highest tertile) and hs-CRP (high-risk category as defined in the AHA/CDC guidelines 5 ) was 3 times greater than in individuals with low to medium levels (first and second tertiles) of Lp-PLA 2 and hs-CRP.
intensify therapy. There is a consensus that individuals with CHD risk Ͼ20% need preventive intervention and therefore CRP measurement will not influence therapy. Screening very-low-risk populations is not recommended and not thought to be cost-effective, although some groups have considered intermediate risk to include 6% to 20%. 27 The ATP III guidelines recommend that calculated 10-year risk for a CHD event be used to determine which patients should receive lipid-lowering therapy and the target level for LDL-C. Two large placebo-controlled randomized clinical trials of statins in high-risk patients have shown that patients benefited from therapy regardless of baseline LDL-C. 28, 29 In the current guidelines, for individuals with LDL-C Ͻ130 mg/dL, drug therapy is not recommended in primary prevention and is considered optional for individuals with CHD or equivalent (ie, 10-year risk estimate Ͼ20%). 19 If high-risk patients with LDL-C Ͻ130 mg/dL receive significant benefit from lipid-lowering drug therapy, as suggested by recent clinical trials, future guidelines may focus more on novel ways to assess CHD risk in low-LDL-C patients to determine who should be selected. This is an important population for CHD prevention, because approximately one third of all events (204 cases in ARIC) occurred in persons with LDL-C Ͻ130 mg/dL.
A post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) suggested that measuring hs-CRP may be useful for targeting statin therapy in primary prevention of acute coronary events. 7 AFCAPS/TexCAPS enrolled middle-aged men and women with average LDL-C and low HDL-C levels, and for individuals with LDL-C below the median (149.1 mg/dL), only those with elevated hs-CRP had reduced risk with lovastatin therapy.
The results from ARIC support the rationale that Lp-PLA 2 and hs-CRP may be useful to identify patients at increased CHD risk who have low LDL-C (Ͻ130 mg/dL) and are not targeted for drug therapy by the current guidelines. ARIC had only a single measurement of Lp-PLA 2 and hs-CRP; associations might have been stronger with multiple measurements of these biomarkers. In addition, the risk for Lp-PLA 2 may have been underestimated because of a lower reliability coefficient for the Lp-PLA 2 manual ELISA than for the hs-CRP automated immunoturbidimetric assay (0.76 versus 0.95). A large prospective randomized trial will test the hypothesis that hs-CRP measurement can identify high-risk patients with LDL-C Ͻ130 mg/dL and no clinical evidence of CHD who may benefit from statin therapy. 30 Although our results support the use of novel blood tests to identify high-risk patients who may benefit from primary prevention, they are also consistent with a putative causal role for both Lp-PLA 2 and hs-CRP in atherogenesis and CHD events. Lp-PLA 2 is bound primarily with LDL, with an increased concentration in small, dense LDL. 9 Small LDL has enhanced penetration into the vessel wall 31 and enhanced susceptibility to oxidation. 32 Lp-PLA 2 is the enzyme responsible for the hydrolysis of oxidized phospholipids and the generation of lysophosphatidylcholine, which can lead to increased expression of adhesion molecules. Thus, increased Lp-PLA 2 in LDL may enhance the atherogenicity of LDL by increasing vascular inflammation. High levels of hs-CRP, which is an acute-phase reactant, may also provoke vascular inflammation, 33 and hs-CRP may preferentially bind to oxidized LDL. 34 Individuals with low LDL-C but high Lp-PLA 2 and hs-CRP may therefore have much greater atherogenicity from LDL than would be expected by the absolute level of LDL-C. Statins lower LDL-C level and LDL particle number, reduce hs-CRP level, 7 and reduce Lp-PLA 2 activity. 35 However, many patients continue to have elevated hs-CRP and Lp-PLA 2 even on statin therapy (Chris J. Packard, DSc, personal communication, 2003) . Other therapies, such as weight loss and high-dose aspirin, also reduce hs-CRP levels. Fibrates have been shown to reduce Lp-PLA 2 activity, 36 and a novel agent that inhibits Lp-PLA 2 is currently in phase II development. 37 Therefore, in addition to potentially identifying high-risk but currently untreated patients who may benefit from therapies such as statins to reduce CHD events, measurement of Lp-PLA 2 and hs-CRP may be useful to identify cohorts of patients for clinical trials to determine whether inhibition of Lp-PLA 2 or reduction/inhibition of hs-CRP reduces CHD events. In summary, both Lp-PLA 2 and hs-CRP may be complementary in identifying middle-aged individuals with high CHD risk but low LDL-C.
